159 related articles for article (PubMed ID: 24806185)
1. Resistance to arsenic therapy in acute promyelocytic leukemia.
Zhu HH; Qin YZ; Huang XJ
N Engl J Med; 2014 May; 370(19):1864-6. PubMed ID: 24806185
[No Abstract] [Full Text] [Related]
2. All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.
Strehl S; König M; Boztug H; Cooper BW; Suzukawa K; Zhang SJ; Chen HY; Attarbaschi A; Dworzak MN
Leukemia; 2013 Jul; 27(7):1606-10. PubMed ID: 23271512
[No Abstract] [Full Text] [Related]
3. APL, a model disease for cancer therapies?
de Thé H; Chelbi-Alix MK
Oncogene; 2001 Oct; 20(49):7136-9. PubMed ID: 11704841
[No Abstract] [Full Text] [Related]
4. Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
Iaccarino L; Ottone T; Divona M; Cicconi L; Cairoli R; Voso MT; Lo-Coco F
Br J Haematol; 2016 Mar; 172(6):909-13. PubMed ID: 26728337
[TBL] [Abstract][Full Text] [Related]
5. Resistance to therapy in acute promyelocytic leukemia.
Lehmann-Che J; Bally C; de Thé H
N Engl J Med; 2014 Sep; 371(12):1170-2. PubMed ID: 25229938
[No Abstract] [Full Text] [Related]
6. Advanced progress on the relationship between RA and its receptors and malignant tumors.
Li M; Sun Y; Guan X; Shu X; Li C
Crit Rev Oncol Hematol; 2014 Sep; 91(3):271-82. PubMed ID: 24793539
[TBL] [Abstract][Full Text] [Related]
7. How acute promyelocytic leukaemia revived arsenic.
Zhu J; Chen Z; Lallemand-Breitenbach V; de Thé H
Nat Rev Cancer; 2002 Sep; 2(9):705-13. PubMed ID: 12209159
[TBL] [Abstract][Full Text] [Related]
8. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
Look AT
J Natl Cancer Inst; 1998 Jan; 90(2):86-8. PubMed ID: 9450562
[No Abstract] [Full Text] [Related]
9. ATRA(ouble) in the treatment of acute promyelocytic leukemia.
Ozpolat B; Lopez-Berestein G; Mehta K
J Biol Regul Homeost Agents; 2001; 15(2):107-22. PubMed ID: 11501968
[TBL] [Abstract][Full Text] [Related]
10. Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia.
Zhang X; Pan J
Ann Hematol; 2017 Apr; 96(4):707-708. PubMed ID: 28154895
[No Abstract] [Full Text] [Related]
11. Mobilization of PML/RARalpha negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide.
Stölzel F; Wermke M; Röllig C; Thiede C; Platzbecker U; Bornhäuser M
Haematologica; 2010 Jan; 95(1):171-2. PubMed ID: 19815840
[No Abstract] [Full Text] [Related]
12. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Vitoux D; Nasr R; de The H
Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
[TBL] [Abstract][Full Text] [Related]
13. GTF2I-RARA is a novel fusion transcript in a t(7;17) variant of acute promyelocytic leukaemia with clinical resistance to retinoic acid.
Li J; Zhong HY; Zhang Y; Xiao L; Bai LH; Liu SF; Zhou GB; Zhang GS
Br J Haematol; 2015 Mar; 168(6):904-8. PubMed ID: 25284716
[No Abstract] [Full Text] [Related]
14. Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy.
Gu BW; Xiong H; Zhou Y; Chen B; Wang L; Dong S; Yu ZY; Lu LF; Zhong M; Yin HF; Zhu GF; Huang W; Ren SX; Gallagher RE; Waxman S; Chen GQ; Wang ZG; Chen Z; Fu G; Chen SJ
Proc Natl Acad Sci U S A; 2002 May; 99(11):7640-5. PubMed ID: 12032336
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid.
Tong H; Li K; Mei C; Wang H; Chen Z; Jin J
Ann Hematol; 2011 Dec; 90(12):1493-4. PubMed ID: 21431323
[No Abstract] [Full Text] [Related]
16. New chemical strategies for overcoming ATRA resistance in APL cells.
Coradini D
Leuk Res; 2007 Mar; 31(3):291-2. PubMed ID: 16919330
[No Abstract] [Full Text] [Related]
17. [Treatment for acute promyelocytic leukemia].
Fujita H
Rinsho Ketsueki; 2014 Oct; 55(10):1817-26. PubMed ID: 25297745
[No Abstract] [Full Text] [Related]
18. Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
Sui M; Zhang Z; Zhou J
Chin Med J (Engl); 2014; 127(19):3503-6. PubMed ID: 25269921
[TBL] [Abstract][Full Text] [Related]
19. [All-trans retinoic acid and arsenic trioxide: their molecular mechanisms of action and updated clinical progress in APL therapy].
Shinagawa K
Rinsho Ketsueki; 2011 Jul; 52(7):469-83. PubMed ID: 21821978
[No Abstract] [Full Text] [Related]
20. Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide.
Nichol JN; Garnier N; Miller WH
Best Pract Res Clin Haematol; 2014 Mar; 27(1):19-31. PubMed ID: 24907014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]